Nocodazole free base
Nocodazole is a microtubule inhibitor; inhibits mitosis.
For research use only. Not for human or veterinary use.
Nocodazole structure
CAS No.: 31430-18-9
Pack sizes & pricing
| Size | Price | SKU | Stock | |
|---|---|---|---|---|
| 200 mg | USD 400.00 | BP-02357-200mg | In stock | Get quote |
| 500 mg | USD 600.00 | BP-02357-500mg | In stock | Get quote |
| 1 g | USD 850.00 | BP-02357-1g | In stock | Get quote |
| 5 g | USD 2,850.00 | BP-02357-5g | In stock | Get quote |
| 10 g | Inquire | BP-02357-10g | In stock | Inquire |
Need another size or custom synthesis? Request a quote.
Description
Nocodazole is a microtubule inhibitor; inhibits mitosis. Also inhibits autophagosome-lysosome fusion.
Biological activity
Nocodazole is an anti-microtubule agent for ABL, ABL (E255K) and ABL (T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively. Nocodazole is a high-affinity ligand for the cancer-related kinases including ABL phosphorylated, c-KIT, BRAF, and MEK with Kd of 0.091 μM, 1.6 μM, 1.8 μM and 1.6 μM, respectively. In addition, the Kd of Nocodazole for ABL (E255K) phosphorylated, ABL (T315I) phosphorylated, BRAF (V600E) and PI3Kγ is 0.12 μM, 0.17 μM, 1.1 μM and 1.5 μM, respectively. Nocodazole induces apoptosis in chronic lymphocytic leukemia cells. Nocodazole inhibits insulin-stimulated glucose transport. Nocodazole decreases apoptosis in some human colon carcinoma cells. Nocodazole impairs the morphology and directionality of migrating medial gan-glionic eminence cells. At high concentrations, nocodazole rapidly depolymerizes microtubules in cells, while low concentrations of nocodazole inhibit microtubule dynamic instability. Mitotic cells incubated with different concentrations of paclitaxel are inhibited from progressing to G1 phase 6 hours after release from the nocodazole block, with a median inhibitory concentration of 4 nM. Nocodazole-pretreated cells exposed to paclitaxel in the absence of nocodazole only form free-floating microtubules, whereas pretreated cells exposed to paclitaxel in the presence of nocodazole-assembled centrosome organize microtubules. Nocodazole disrupts microtubules by binding to β-tubulin. Nocodazole prevents the formation of one of the two interchain disulfide linkages. Nocodazole impairs the transport of vesicles. Nocodazole suppress METH-induced cell death and lysosomal dysfunction. METH-induced cell death is significantly decreased by Nocodazole pretreatment in comparison to METH alone. The tumor volume and tumor weight of the mice treated with Ketoconazole plus Nocodazole are significantly reduced as compared with those treated with Ketoconazole or Nocodazole alone. Combined treatment with Ketoconazole plus Nocodazole strongly enhances apoptosis of COLO 205 tumor xenografts treated with Ketoconazole or Nocodazole alone. The tumor volume and tumor weight of the mice treated with Ketoconazole plus Nocodazole are significantly reduced as compared with those treated with Ketoconazole or Nocodazole alone. Combined treatment with Ketoconazole plus Nocodazole strongly enhances apoptosis of COLO 205 tumor xenografts treated with Ketoconazole or Nocodazole alone.
Identifiers
- SMILES
-
COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3 - InChIKey
-
KYRVNWMVYQXFEU-UHFFFAOYSA-N
Specifications
- MW (average)
- 301.3200
- Formula
- C14H11N3O3S
- CAS No.
- 31430-18-9
- Physical state
- Solid
- Color
- Light yellow to brown
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder -20℃ 2 years; In solvent -20℃ 1 month;
Solubility
Soluble in DMSO
- In vitro
- DMSO : 16.67 mg/mL
Documents
References
Same target
Search Bcr-AblSame research area
Search Cancer- BP-00001 KN-92 free base · >98%
- BP-00084 ORIC-944 free base · >98%
- BP-00756 PF-07853578 free base · >98%
- BP-00771A dTAGV-1 hydrochloride salt · >98%
- BP-00882 OPB-171775 free base · HPLC >98%, ee>98%
- BP-00998 BGB-116673 analog free base · >98%
- BP-01217 RAD51-IN-2 free base · >98%
- BP-01260 Rezivertinib free base · >98%